BR112013027764B1 - Cartucho de grampo para uso com um grampeador cirúrgico - Google Patents
Cartucho de grampo para uso com um grampeador cirúrgico Download PDFInfo
- Publication number
- BR112013027764B1 BR112013027764B1 BR112013027764-5A BR112013027764A BR112013027764B1 BR 112013027764 B1 BR112013027764 B1 BR 112013027764B1 BR 112013027764 A BR112013027764 A BR 112013027764A BR 112013027764 B1 BR112013027764 B1 BR 112013027764B1
- Authority
- BR
- Brazil
- Prior art keywords
- staple cartridge
- staple
- staples
- cartridge
- layer
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 230000001960 triggered effect Effects 0.000 claims description 16
- 239000004744 fabric Substances 0.000 abstract description 635
- 210000000078 claw Anatomy 0.000 abstract 3
- 239000010410 layer Substances 0.000 description 667
- 210000001519 tissue Anatomy 0.000 description 555
- 239000011159 matrix material Substances 0.000 description 325
- 239000000463 material Substances 0.000 description 232
- 238000010304 firing Methods 0.000 description 221
- 210000001847 jaw Anatomy 0.000 description 191
- 238000005520 cutting process Methods 0.000 description 115
- 230000014759 maintenance of location Effects 0.000 description 102
- 229920000954 Polyglycolide Polymers 0.000 description 88
- 239000004633 polyglycolic acid Substances 0.000 description 86
- 230000033001 locomotion Effects 0.000 description 83
- 230000036961 partial effect Effects 0.000 description 71
- 229920001610 polycaprolactone Polymers 0.000 description 69
- 239000004632 polycaprolactone Substances 0.000 description 69
- 229920000747 poly(lactic acid) Polymers 0.000 description 55
- 239000000203 mixture Substances 0.000 description 54
- 239000000853 adhesive Substances 0.000 description 52
- 230000001070 adhesive effect Effects 0.000 description 52
- 238000010586 diagram Methods 0.000 description 48
- 239000003814 drug Substances 0.000 description 48
- 230000006835 compression Effects 0.000 description 47
- 238000007906 compression Methods 0.000 description 47
- 229920000117 poly(dioxanone) Polymers 0.000 description 47
- 229940079593 drug Drugs 0.000 description 45
- 238000000034 method Methods 0.000 description 45
- 230000007246 mechanism Effects 0.000 description 44
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 39
- 230000008569 process Effects 0.000 description 33
- 238000011068 loading method Methods 0.000 description 32
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 29
- 239000000622 polydioxanone Substances 0.000 description 29
- 229920000642 polymer Polymers 0.000 description 29
- 239000006260 foam Substances 0.000 description 28
- 229920003023 plastic Polymers 0.000 description 27
- 239000004033 plastic Substances 0.000 description 27
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 27
- -1 17-4 & 17-7 Substances 0.000 description 26
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 25
- 229920001432 poly(L-lactide) Polymers 0.000 description 25
- 230000001681 protective effect Effects 0.000 description 24
- 239000011148 porous material Substances 0.000 description 20
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 18
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 18
- 239000004626 polylactic acid Substances 0.000 description 18
- 239000010935 stainless steel Substances 0.000 description 18
- 229910001220 stainless steel Inorganic materials 0.000 description 18
- 239000010936 titanium Substances 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 230000007423 decrease Effects 0.000 description 16
- 230000002439 hemostatic effect Effects 0.000 description 14
- 229910052751 metal Inorganic materials 0.000 description 14
- 239000002184 metal Substances 0.000 description 14
- 239000012779 reinforcing material Substances 0.000 description 14
- 102000009123 Fibrin Human genes 0.000 description 13
- 108010073385 Fibrin Proteins 0.000 description 13
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 13
- 238000005538 encapsulation Methods 0.000 description 13
- 229950003499 fibrin Drugs 0.000 description 13
- 239000000017 hydrogel Substances 0.000 description 13
- 230000000717 retained effect Effects 0.000 description 13
- 210000003739 neck Anatomy 0.000 description 12
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 230000008093 supporting effect Effects 0.000 description 11
- 229910052719 titanium Inorganic materials 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 239000006261 foam material Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000004627 regenerated cellulose Substances 0.000 description 10
- 229920001198 elastomeric copolymer Polymers 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000010894 electron beam technology Methods 0.000 description 8
- 229920001059 synthetic polymer Polymers 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 8
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 7
- 229910001200 Ferrotitanium Inorganic materials 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 7
- 229920001296 polysiloxane Polymers 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000004696 Poly ether ether ketone Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 6
- 238000001746 injection moulding Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000000149 penetrating effect Effects 0.000 description 6
- 229920002530 polyetherether ketone Polymers 0.000 description 6
- 230000002787 reinforcement Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 5
- 238000005452 bending Methods 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000004373 mandible Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 229960003500 triclosan Drugs 0.000 description 5
- 229910000831 Steel Inorganic materials 0.000 description 4
- 229940030225 antihemorrhagics Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000013536 elastomeric material Substances 0.000 description 4
- 239000002874 hemostatic agent Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000007769 metal material Substances 0.000 description 3
- 230000003641 microbiacidal effect Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000223 polyglycerol Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000012858 resilient material Substances 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 229940116351 sebacate Drugs 0.000 description 3
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 229910000679 solder Inorganic materials 0.000 description 3
- 210000003813 thumb Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920004738 ULTEM® Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 238000005219 brazing Methods 0.000 description 2
- 229910010293 ceramic material Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000881 depressing effect Effects 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002991 molded plastic Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920009441 perflouroethylene propylene Polymers 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001195 polyisoprene Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 229920002620 polyvinyl fluoride Polymers 0.000 description 2
- 229920000131 polyvinylidene Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- KKGSHHDRPRINNY-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1.O=C1COCCO1 KKGSHHDRPRINNY-UHFFFAOYSA-N 0.000 description 1
- MFRCZYUUKMFJQJ-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;1,3-dioxan-2-one Chemical compound O=C1OCCCO1.O=C1COC(=O)CO1 MFRCZYUUKMFJQJ-UHFFFAOYSA-N 0.000 description 1
- 229910001094 6061 aluminium alloy Inorganic materials 0.000 description 1
- 229910001008 7075 aluminium alloy Inorganic materials 0.000 description 1
- UBDHSURDYAETAL-UHFFFAOYSA-N 8-aminonaphthalene-1,3,6-trisulfonic acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(N)=CC(S(O)(=O)=O)=CC2=C1 UBDHSURDYAETAL-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920004937 Dexon® Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- IWDQPCIQCXRBQP-UHFFFAOYSA-M Fenaminosulf Chemical compound [Na+].CN(C)C1=CC=C(N=NS([O-])(=O)=O)C=C1 IWDQPCIQCXRBQP-UHFFFAOYSA-M 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 239000004775 Tyvek Substances 0.000 description 1
- 229920000690 Tyvek Polymers 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000000396 iron Nutrition 0.000 description 1
- 239000002648 laminated material Substances 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000012830 laparoscopic surgical procedure Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 238000012978 minimally invasive surgical procedure Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- ORQBXQOJMQIAOY-UHFFFAOYSA-N nobelium Chemical compound [No] ORQBXQOJMQIAOY-UHFFFAOYSA-N 0.000 description 1
- 238000002355 open surgical procedure Methods 0.000 description 1
- 229920001279 poly(ester amides) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000013354 porous framework Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 229940009188 silver Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 230000003874 surgical anastomosis Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Landscapes
- Surgical Instruments (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/097,873 US8740038B2 (en) | 2010-09-30 | 2011-04-29 | Staple cartridge comprising a releasable portion |
US13/097,873 | 2011-04-29 | ||
PCT/US2012/033446 WO2012148702A2 (en) | 2010-09-30 | 2012-04-13 | Staple cartridge comprising a releasable portion |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013027764A2 BR112013027764A2 (enrdf_load_stackoverflow) | 2017-01-03 |
BR112013027764B1 true BR112013027764B1 (pt) | 2021-09-21 |
Family
ID=90730568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013027764-5A BR112013027764B1 (pt) | 2011-04-29 | 2012-04-13 | Cartucho de grampo para uso com um grampeador cirúrgico |
Country Status (1)
Country | Link |
---|---|
BR (1) | BR112013027764B1 (enrdf_load_stackoverflow) |
-
2012
- 2012-04-13 BR BR112013027764-5A patent/BR112013027764B1/pt active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
BR112013027764A2 (enrdf_load_stackoverflow) | 2017-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240260962A1 (en) | Fastener cartridge comprising a tissue thickness compensator and a gap setting element | |
JP6374040B2 (ja) | 圧縮可能なステープルカートリッジアセンブリ | |
JP6370872B2 (ja) | 解放可能部分を含むステープルカートリッジ | |
BR112013027757B1 (pt) | Cartucho de grampos para uso com um grampeador cirúrgico | |
JP6392319B2 (ja) | 締結具カートリッジアセンブリ | |
JP6165737B2 (ja) | ステープル留め器具用湾曲エンドエフェクタ | |
JP6033847B2 (ja) | 外科用ステープラー用の組織厚さコンペンセーター | |
JP6081465B2 (ja) | 潰れることができるデッキ構造を含むステープルカートリッジ | |
BR112013027896B1 (pt) | Cartucho de grampo para uso com um grampeador cirúrgico | |
BR112013027794B1 (pt) | Conjunto de cartucho de grampos | |
BR112015024515B1 (pt) | Conjunto de cartucho de prendedores | |
BR112013027761B1 (pt) | Instrumento cirúrgico e atuador de extremidade | |
BR112015024582B1 (pt) | Cartucho de prendedores e atuador de extremidade | |
BR112014024303B1 (pt) | Grampeador cirúrgico | |
BR112014024121B1 (pt) | Compensador de espessura de tecido para uso com um grampeador cirúrgico circular e sistema de grampeamento cirúrgico circular | |
BR112013007621B1 (pt) | Cartucho de grampos para um instrumento cirúrgico | |
BR112013027853B1 (pt) | cartucho de grampo para uso com um grampeador cirúrgico | |
JP6211674B2 (ja) | 位置合わせ部材を含む圧縮可能ステープルカートリッジ | |
BR112014024305B1 (pt) | Unidade de carregamento descartável para um grampeador cirúrgico e grampeador cirúrgico | |
BR112013027810B1 (pt) | Atuador de extremidade para um grampeador cirúrgico | |
BR112013027764B1 (pt) | Cartucho de grampo para uso com um grampeador cirúrgico | |
BR112013027874B1 (pt) | Cartucho de grampos para uso com um grampeador cirúrgico | |
BR112013027753B1 (pt) | instrumento cirúrgico e grampeador cirúrgico | |
BR112014006991B1 (pt) | atuador de extremidade para um instrumento de grampeamento cirúrgico | |
BR112014007047B1 (pt) | Atuador de extremidade de um instrumento de grampeamento cirúrgico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/04/2012, OBSERVADAS AS CONDICOES LEGAIS. |